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Abstract
Background—Medication adherence may be a proxy for healthy behaviors and other factors 
that affect outcomes. Prior studies of the association between placebo adherence and health 
outcomes have been limited primarily to men enrolled in clinical trials and cardiovascular disease 
outcomes. We examined associations between adherence to placebo and the risk of fracture, 
coronary heart disease, cancer, and all-cause mortality in the two Women’s Health Initiative 
(WHI) hormone therapy randomized trials.
Methods—Postmenopausal women randomized to placebo with adherence measured at least 
once were eligible for analysis. Time-varying adherence was assessed by dispensing history and 
pill counts. Outcome adjudication was based on physician review of medical records. Cox 
proportional hazards models evaluated the relation between high adherence (≥80%) to placebo and 
various outcomes, referent to low adherence (<80%).
Results—A total of 13,444 postmenopausal women were under observation for 106,066 person-
years. High placebo adherence was inversely associated with most outcomes including hip fracture 
(HR 0.50, 95% CI 0.33–0.78), myocardial infarction (HR 0.69, 95% CI 0.50–0.95), cancer death 
(HR 0.60, 95% CI 0.43–0.82) and all cause mortality (HR 0.64, 95% CI 0.51–0.80) after 
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adjustment for potential confounders. Women with low adherence to placebo were 20% more 
likely to have low adherence to statins and osteoporosis medications.
Conclusions—In the WHI clinical trials, high adherence to placebo was associated with 
favorable clinical outcomes and mortality. Until the healthy behaviors and/or other factors for 
which high adherence is a proxy can be better elucidated, caution is warranted when interpreting 
the magnitude of benefit of medication adherence.
Keywords
fracture; adherence; placebo; compliance; mortality; myocardial infarction; malignancy; 
osteoporosis
Introduction
Medication adherence is an important topic within the medical community, with numerous 
studies demonstrating suboptimal adherence with a wide variety of drugs, including oral 
osteoporosis medications and therapies for hyperlipidemia and hypertension (1–7). Between 
25 and 50% of new users of these medications discontinue within one year of initiation. The 
potential importance of this finding is underscored by observational studies demonstrating 
significant differences in the risk for fracture, cardiovascular events, and mortality 
comparing adherent and non-adherent persons (8–12).
However, a largely unexplored potential source of confounding related to medication 
adherence is the possibility that other healthy behaviors are also present in persons adherent 
to medications. This might lead to beneficial effects independent of the medication effect, 
which has been called a “healthy adherer” effect. In fact, randomized, placebo-controlled 
trials (RCTs) evaluating drug therapy, mainly after myocardial infarction (MI) in men, have 
demonstrated lower mortality risk in patients with higher placebo adherence (13–15) lending 
credence to the possibility that good adherence itself is associated with a lower risk of 
adverse outcomes. The healthy adherer effect is hypothesized to be a surrogate for other 
healthy behaviors (16, 17), which may or may not be able to be measured and controlled for 
in analyses of observational data or trials. It is not clear if the healthy adherer effect extends 
to clinical outcomes other than MI, to healthy populations, or to women.
To examine these issues, we used data from the placebo arms of the two hormone therapy 
(HT) randomized, placebo-controlled trials of the Women’s Health Initiative (WHI), which 
enrolled relatively healthy postmenopausal women. We studied the relationship between 
placebo adherence and the risk for fracture, coronary heart disease (CHD), malignancy, 
cause-specific mortality and all-cause mortality. We also examined the extent to which the 
healthy adherer effect carried over to other medication taking behavior for hyperlipidemia 
and osteoporosis. We selected these conditions because they are chronic and asymptomatic; 
thus, good adherence is more likely due to a healthy adherer effect and less likely to be 
attributable to symptom-relieving behavior.
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Cohort and Patient Eligibility Criteria
All women participating in the two hormone therapy (HT) trials of the WHI who were 
randomized to placebo were eligible for analysis. More complete descriptions of the HT 
trials (18–20), patient recruitment and study implementation have been previously published 
(21). A three month wash-out period was required for women presenting with current 
hormone therapy use. The WHI trial evaluating estrogen plus progestin randomized 16,608 
postmenopausal women with no prior hysterectomy to active hormone therapy or placebo. 
The separate WHI trial evaluating estrogen alone randomized 10,739 postmenopausal 
women with prior hysterectomy to active hormone therapy or placebo. Differences in the 
characteristics of participants in these two trials have been previously described (19). 
Women were not eligible for this analysis if they experienced an outcome of interest or 
withdrew from the HT study before the first measurement of adherence.
All study pills, hormones or identical appearing placebo, were dispensed at the WHI clinical 
centers using a computerized dispensing system, blinding both participants and clinical staff 
to randomization allocation. For breast cancer safety, all participants were required to have 
annual clinical breast exams (performed at the clinical centers) and annual screening 
mammography.
Characterization of Adherence
For this analysis, and consistent with recommendations from the International Society of 
Pharmacoeconomics and Outcomes Research (ISPOR), adherence was used as a general 
term and defined by the extent to which a patient’s behavior coincides with the prescribed 
treatment regimen (22). It can be quantified as persistence, which captures the length of time 
a patient continues with therapy, or as compliance, typically quantified as a medication 
possession ratio (MPR), or as the proportion of days covered (PDC). The MPR and the PDC 
are equivalent if the MPR is capped at a maximum of 100%.
For this analysis, we quantified adherence as the PDC, calculated as the number of days for 
which the study medication was dispensed (based on dispensing history) minus the number 
of days of untaken pills (based on remaining study pills returned) divided by the number of 
days between visits. While enrolled in the study, women had an annual clinic visit and a 
semiannual contact by phone, mail, or in-person clinic visit. At each clinic visit, women 
were asked to return all their study medication bottles. To assess PDC, pill counts in the 
returned medication bottles were evaluated. From 1993–1996, a pill counter was used; 
subsequently, pill weighing was used to estimate remaining pill number. This process was 
not observed by or discussed with participants. However, a PDC below 80% initiated future 
staff efforts to increase adherence for both the placebo and intervention arms, and study 
personnel remained blinded to treatment arm. The mean interval between study visits at 
which adherence was assessed was approximately 6 months; 95% of intervals over which 
adherence was assessed were one year or less.
Although selection of an adherence threshold is arbitrary, we initially categorized PDC as 
<= 50%, >50 and < 80%, and >= 80%, following prior conventions (8, 23). Because some 
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outcome models were unstable, with <10 events in at least one of the lower two categories 
of adherence, PDC was subsequently collapsed to two categories of < 80% vs. >= 80%. The 
main exposure variable of interest was cumulative (i.e. average) PDC since the beginning of 
observation. Since there were multiple adherence assessments available per participant, PDC 
varied over time in the analysis. As part of a sensitivity analysis, we examined outcomes in 
relation to adherence only for the most recent time interval; as results were minimally 
different compared to the main analysis, these data are not presented.
Outcome Assessment
Outcomes of interest were hip, clinical vertebral, and distal forearm (i.e. wrist) fracture, 
CHD (myocardial infarction or CHD death), invasive breast cancer, colorectal cancer, all 
invasive cancer, cancer death and all-cause mortality. Case definitions for these outcomes 
were as defined in the WHI protocol. Self reports of clinical outcomes were verified by 
medical record and pathology report review by trained physician adjudicators. Outcomes 
were then centrally reviewed by physicians based upon medical record review (24–26), with 
blinding to randomization allocation.
Statistical Analysis
Descriptive statistics compared demographics, comorbidities, medication use, and other risk 
factors across adherence categories. Proportional hazards models modeled the time-varying 
relationship between adherence to placebo and outcomes of interest (27). Adherence prior to 
fracture has been shown to differ from adherence after the fracture in a previous report (8), 
so adherence was measured for all participants prior to events. Observation time began at the 
time of the first measurement of adherence and continued until a participant died or became 
lost to follow-up. In cases were a participant did not bring her pills in for a particular visit, 
the adherence value from the previous visit was carried forward until her next known 
adherence value. Age and BMI were modeled continuously; all other covariates were 
modeled categorically (categories shown as in table 1). Covariates measured at baseline 
were selected based upon a-priori interest and their inclusion in previous WHI reports 
examining the same outcomes; covariates used in the analysis are reported in the footnote to 
Table 2.
We then examined the correlation between placebo adherence and adherence to 
hyperlipidemia and osteoporosis medications in the subset of clinical trial participants taking 
medications for these conditions (N=883 and n=158, respectively). In the WHI, use of non-
study medications was not captured with sufficient detail that allowed for calculation of their 
PDC. Therefore, adherence with hyperlipidemia and osteoporosis medications was 
quantified as one-year persistence, which was determined by self-report and medication 
bottle review at baseline and one year later. We defined high persistence with statins and 
osteoporosis pharmacotherapy as individuals remaining on therapy at one year.
Application of external adjustment methods to control for the healthy adherer effect in an 
observational analysis
Assuming women who were high placebo adherers were more likely to adhere to 
osteoporosis and lipid medications, this suggests that the behaviors and factors associated 
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with healthy adherer effect may be in part independent of the medication itself and thus 
generalizable across medication classes. For this reason, we considered higher adherence 
with osteoporosis and lipid medications as a proxy for unmeasured confounders related to 
the healthy adherer effect. An unmeasured confounder can be controlled for using external 
adjustment methods (28) by using information obtained from other studies where that 
confounder was measured to estimate 1) the differential prevalence of the confounder 
between groups and 2) the association between the confounder and the outcome. We 
demonstrated how one might use our results (from the placebo group) to adjust for the 
healthy adherer effect in an observational analysis of adherence to an active medication (e.g. 
hormone therapy) where there is no placebo group in which to directly measure adherence 
behavior. In this example, we use the result from the placebo adherence association with hip 
fractures, and the differential prevalence to osteoporosis and lipid medications between 
women adherent and non-adherent to placebo, to more fully adjust the effect of adherence to 
HT on fractures.
Using identical methods to those described above for women randomized to placebo, we 
studied women in the HT arm of the WHI trial to estimate the relationship between 
adherence to HT and hip fracture. We compared women highly adherent (>=80%) to those 
less adherent (<80%) to HT, adjusting for the same confounders as for our placebo-
adherence models (Table 2). External adjustment techniques (28), with the confounder of 
interest being non-adherence behavior, were used to yield a healthy adherer-adjusted HT-hip 
fracture result. In other words, the ‘missing’ confounder that we controlled using external 
adjustment represented whatever factor(s) for which placebo adherence served as a proxy. 
This healthy adherer adjusted result was compared to the previously-reported result for the 
association between HT and hip fracture (18, 20, 29).
Results
Descriptive characteristics of the 13,444 WHI HT trial participants receiving placebo are in 
Table 1. Older women, those better educated, and with higher household incomes were more 
adherent with the placebo regimen. Adherent women were less likely to smoke and consume 
low amounts of fruits and vegetables and had better self-reported health. Adherent women 
were more likely to have had pap smears and colonoscopies and to have seen a healthcare 
provider in the previous year. In general, differences between groups defined by adherence 
were modest. Some statistically significant differences were of small magnitude and of little 
clinical significance.
The pattern of adherence over the course of the study is shown in Figure 1. On average, a 
majority of women were highly adherent to study medication, although adherence decreased 
over time. Five years into the trial, about 25% of women were < 80% adherent. Women 
reporting baseline moderate to severe climacteric symptoms had similar adherence to 
placebo as others (data not shown).
The main results of the study are shown in Table 2. Adherence to placebo was significantly 
and inversely associated with all-cause mortality, hip fracture, myocardial infarction, 
invasive breast cancer, and cancer-related death. Non-significant trends suggested a reduced 
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incidence of all other outcomes except for wrist fracture and colon cancer. The crude and 
adjusted hazard ratios were minimally different for most outcomes. In analyses for which we 
did have adequate numbers of outcome events to examine 3 categories of adherence (0–
50%, >50–<80%, >= 80%), results for intermediate adherence (PDC 50–80%) were in-
between those for high PDC and low PDC.
Table 3 shows the association between adherence to placebo and persistence with statins and 
osteoporosis medications. Women highly adherent to placebo dispensed through the clinical 
trial had a 20% greater absolute difference in persistence with medications for 
hyperlipidemia and osteoporosis (prescribed for clinical indications) compared to women 
not highly adherent to placebo.
We could not directly adjust the HT-hip fracture result with the information on adherence to 
other medications given that only a small proportion of women were taking these other 
medications. However, to demonstrate how one might adjust for the healthy adherer effect in 
the analysis of the effect of HT on hip fracture, we used external adjustment methods. The 
crude hazard ratio for the association between high adherence to HT and hip fracture was 
0.43 (95% CI 0.28 – 0.66). After controlling for factors described in the footnote of Table 2, 
the adjusted hazard ratio associated with high vs. low HT adherence was 0.54 (95% CI 
0.34–0.84). Based on the observed prevalence of low adherence to osteoporosis medication 
of 50% and 30% among women with low and high placebo adherence, results in Table 4 
yielded a more fully-adjusted hazard ratio of 0.62. This change in the hazard ratio from 0.54 
to 0.62 is consistent with the external adjustment procedure providing some additional 
control for confounding related to the healthy adherer effect. Similar results were observed 
applying the differential prevalence of low adherence to statins.
Discussion
Among postmenopausal women randomized to placebo in the two randomized HT trials of 
the WHI, we found a strong and significant inverse association between adherence to 
placebo and hip fracture, CHD, invasive breast cancer, cancer death, and all-cause mortality. 
The magnitude of this effect was greatest for hip fracture. Based upon these results, the 
healthy adherer effect may be an important factor that could confound observational 
analyses, leading to over-estimation of medication benefits. Analyzing a clinical trial only 
among the subgroup of adherent patients, rather than by intent-to-treat, may likewise be 
biased.
The association between placebo adherence in randomized controlled trials and mortality 
risk has been examined in at least eight previous reports. As summarized in a recent meta-
analyses, high adherence to placebo was associated with lower all-cause mortality (HR 0.45, 
95% CI 0.38–0.54) (12). Although the eight trials included enrolled 1167 participants with 
636 deaths, only 240 women were included, among whom 19 deaths occurred. In one of 
these trials, adherence was measured by self report only, and adherence in a second was 
based on clinician’s impression. Objective measurement of adherence may differ from self 
reports or subjective assessments (30). Even despite some methodologic heterogeneity in 
how adherence was assessed, these prior reports support an association with placebo 
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adherence and lower mortality in men participating in drug therapy trials following MI. 
Only limited evidence is available regarding placebo adherence in healthier populations and 
on other clinical outcomes including mortality. Among the few studies conducted in women 
and consistent with our findings, an analysis of adherence to placebo in postmenpausal 
women participating in an osteoporosis clinical trial suggested a lower rate of hip fracture 
associated with placebo adherence, but there were few hip fracture events and results were 
not statistically significant (31).
Our study was not designed to elucidate behaviors and other risk factor for which 
medication adherence may be a proxy, but factors associated with adherence to calcium and 
Vitamin D in the WHI has been described (32). However, factors related to adherence with 
these supplements may differ compared to adherence with prescription medications like HT. 
Nevertheless, we can offer some observations about behaviors that did not account for the 
healthy adherer effect we observed. The healthy adherer adjusted results were minimally 
different than the unadjusted results for most outcomes, suggesting that none of the baseline 
factors we controlled for accounted for the healthy adherer effect; these included age, race, 
income, education, marital status, occupation, health insurance, health care seeking 
behavior, preventive services utilization, health behaviors like smoking and alcohol, 
exercise, diet, medical conditions and medications, and depression
Although it is possible that the healthy adherer effect may be a proxy for unmeasured 
behaviors and health habits that WHI did not collect or that varied substantially over time, 
these effects may not affect all outcomes. For example, despite the strong association seen 
with placebo adherence and hip fracture, there was no similar inverse relation between 
adherence and wrist fractures or colon cancer. Wrist fractures have a weaker association 
with osteoporosis than hip and vertebral fractures (33) and different risk factors (34); wrist 
fractures typically occur in healthier, more active women. It is also possible that the 
differential association between adherence and hip versus wrist fracture may be related to 
major changes in health state (i.e. a ‘sick stopper’ effect), whereby declining health, 
worsening comorbidities, and an associated competing focus on other health issues results in 
patients changing patterns of medication use, perhaps becoming less adherent (35). These 
changes in health status may be more strongly associated with certain outcomes (e.g. hip 
fracture) than others (e.g. wrist fracture). The importance and magnitude of the healthy 
adherer effect also may vary by patient population. For example, an observational study of 
patients registered in a large database of post-MI patients in Ontario did not find evidence 
that outcome benefits were mediated by “healthy adherer” behavioral attributes (36).
Additional examination of time-varying confounders may be fruitful to better understand the 
pathway by which medication adherence as a behavior mediates its protective effect. We 
were unable to pursue this possibility because repeated measures of baseline factors were 
not made very frequently (i.e. every 1–3 years). Future studies that can link clinical trials or 
observational registries to administrative claims data, where data capture is essentially 
continuous, may yield a better understanding of the healthy adherer effect. Such a linkage 
with administrative data could allow better understanding of major and rapid changes in 
health state (e.g. new comorbidities, recent hospitalizations) and minimize loss to follow-up, 
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although administrative data may be somewhat limited in providing clinically rich 
information.
Despite our lack of understanding of the pathway by which the ‘healthy adherer’ effect 
operates, it may nevertheless be possible to at least partially control for its effect using 
external adjustment (37, 38). In our study, the unmeasured confounder was adherence 
behavior. This information was used to adjust the association between high adherence to HT 
and hip fracture (HR = 0.54) to yield a healthy adherer-adjusted hazard ratio of 0.62. 
Depending on the ‘true’ value of the association of placebo adherence and hip fracture risk, 
the externally-adjusted HT-hip fracture hazard ratio may have ranged from 0.57 to as high as 
0.68. Compared to our initially adjusted results, this result was closer to the result from the 
WHI HT RCT, which in the estrogen arm was 0.61 (0.41–0.91) (29) and in the estrogen
+progestin arm was 0.67 (95% CI 0.47–0.96) (18, 20). Without the adjustment for the 
healthy adherer effect, the benefit of HT was over-estimated. External adjustment may 
provide an approach to controlling for the healthy adherer effect, independent of drug effect, 
and should be further examined in future studies. Of potential importance, adherence to 
hyperlipidemia and osteoporosis medications in WHI was self-reported, and some of the 
adherence data for these medications was missing (up to 15% of women). We categorized 
these missing data as non-persistence, given that the occurrence of missing data was 
strongly associated with non-adherence to placebo study medication. Additionally, our 
estimates of adherence to hyperlipidemia and osteoporosis medications were from women 
taking these at baseline, many of whom were likely to have been longstanding, prevalent 
users. A more robust measure of association of adherence to these medications, studying 
new users and deriving more precise information from a data source such as a pharmacy 
claims database, might allow for better estimation of adherence behavior and thus permit 
more complete adjustment.
Study strengths include a large, ethnically diverse study population of well characterized 
postmenopausal women at a wide range of ages from 40 U.S. centers. Adherence to trial 
medication or placebo was rigorously determined using a prospectively defined procedure 
and not based on self report. Clinical outcomes were rigorously ascertained. Even for 
women who withdrew from the WHI, follow-up on the mortality endpoint was available in 
98% of participants. Additionally, we were able to adjust for a broad and comprehensive set 
of healthy behaviors that have been postulated to explain at least some of the ‘healthy 
adherer’ effect, although many of these factors were measured only at baseline. Despite 
these strengths, our study has some potential limitations. Small number of events for some 
outcomes (e.g. colorectal cancer) required collapsing adherence categories into 2 levels, a 
convention we followed for all outcome analyses for consistency. Women were censored at 
the time they did not return for any further WHI study visits. If one assumes that these 
women were non-adherent, then it is likely that our results are conservative compared to the 
estimates we would obtain if we imputed non-adherence for these women and allowed them 
to remain in the analysis. Additionally, and despite the diverse nature of the more than 
13,000 WHI clinical trial participants represented in our analysis, our findings may have 
limited generalizability to non-trial settings, although this would not compromise the 
internal validity of our results. Finally, adherence to a medication provided by a study like 
WHI may be different, and may be associated with different outcomes, than adherence to a 
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medication prescribed for any other reason, although the direction of any potential bias is 
difficult to predict.
In conclusion, we report that adherence to placebo was associated with improved clinical 
outcomes and lower all-cause mortality, suggesting that the healthy adherer effect is 
important across a broader set of outcomes than previously reported, and is relevant for 
community-dwelling women as well as men. This work underscores the importance of 
developing, as part of a future research agenda, a better understanding of the healthy adherer 
effect, both in terms of the behaviors or factors that mediate the observed beneficial effects, 
and as well as how adherence changes over time in relation to changes in health states. In 
the meantime, we have presented one approach to adjusting for this healthy adherer effect to 
provide more valid estimates of benefits due to the medication rather than factors solely 
associated with adherence itself.
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Proportion of Women with Various Levels of Adherence to Study Medication (Placebo) 
over the Course of the WHI Randomized Trial
The numbers at the bottom of the figure describes the sample size under observation at that 
time point
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Table 4
Fully-Adjusted Association between High Adherence to Hormone Therapy and Hip Fracture after External 
Adjustment for Low Adherence Behaviors
Formula RRplacebo RRfull
1 / 0.50 = 2.0 0.62*
1 / 0.33 = 3.03 0.68
1 / 0.78 = 1.28 0.57
*
example calculation per (28), 
RRadj=0.54 (observed adjusted association between high adherence to HT and hip fracture)
Ph=0.30 (prevalence of poor adherence behavior among women with high adherence to placebo, i.e., prevalence of low/missing persistence with 
osteoporosis medications from table 3)
Pl=0.50 (prevalence of poor adherence behavior among women with low adherence to placebo, i.e., prevalence of low/missing persistence with 
osteoporosis medications from table 3)
RRplacebo=0.50 (95%CI=0.33–0.78), inverted observed adjusted association between poor adherence to placebo and hip fracture, observed in 
Table 2
RRfull=fully adjusted association between HT and hip fracture, after controlling for residual confounding (adherence behavior identified by 
adherence to osteoporosis pharmacotherapy).
Applying differential adherence to statins identifies similar externally-adjusted results, i.e., RR=0.63, with point estimates for the RR ranging from 
0.57 to 0.69 depending on the true value of RRplacebo
Med Care. Author manuscript; available in PMC 2014 November 03.
